Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial

ConclusionOnce-monthly galcanezumab significantly reduced the frequency of migraine headache days with moderate-to-severe or severe headache, migraine headache days with migraine-associated symptoms, and migraine headache days during menstrual periods in Japanese patients with episodic migraine, consistent with results from global studies.Trial Registration: ClinicalTrials.gov (NCT02959177).

http://link.springer.com/10.1007/s40120-022-00410-3

Source: Neurology and Therapy - October 20, 2022 Category: Neurology Source Type: research